Discussion
Lafora bodies seen in light microscopy of skin biopsy
when taken in accordance with appropriate clinical data
are diagnostic for Lafora Disease. The presence of Lafora
bodies alone, independent of the clinical context, is not
diagnostic [
1]. As discussed earlier, similar appearances
can also be seen in other diseases and some physiological
bodily processes. These bodies may be seen in diseases
such as double athetosis, ALS, type 4 glycogen depot
disease, and adult polyglycosan body disease, whereas
similar polyglycosan bodies can also be seen in the normal
aging process as corpora amylacea [
5]. Therefore, current
histopathologic data should not be evaluated independent
of the clinical context. The PAS positive staining of these
bodies, as we have shown in our case, indicates that they
are carbohydrate-rich at significant levels [
3,
4,
6,
7]. Former
electron microscopic evaluations have shown that the
Lafora body is almost entirely composed of complex
glucose molecules, indicating that the carbohydrate content
is almost entirely polyglycosan (glucose polysaccharides) [
1,
8]. EPM2A (6q24), EPM2B (6q22.3) and PRDM8
(shown only in one family) are said to be responsible for
the mutation that cause these polyglycosans to accumulate
[
2]. The diagnosis of Lafora disease can also be made by
the observation of the polyglycosan cytoplasmic inclusion
bodies in the brain, liver, and skeletal muscle biopsies
[
1,
5,
8]. On the other hand, polyglycosan bodies seen in
Lafora disease are separated from other diseases in which
polyglycosan bodies are also observed, by the location
of accumulation. In Lafora disease, polyglycosan bodies
are concentrated on the perikaryon and dendrites area of
the neuron while in adult polyglycosan body disease and
corpora amylacea, the polyglycosan bodies are limited to
the axonal region [
1]. Why they do not proceed along the
same path as the other polyglycosans is curious in Lafora
Disease. Although we need more work to understand the
etiopathogenesis of Lafora disease, we would like to draw
attention to the importance of skin biopsy in the differential
diagnosis of young patients with clinically refractory
epilepsy, myoclonus, and cognitive decline.
CONFLICT of INTEREST
The authors declare no conflict of interest.
AUTHORSHIP CONTRIBUTIONS
Concept: EK, PA, Design: PA, Data collection or processing:
PA, ÖEÖ, ÇT, Analysis or Interpretation: EK, PA, Literature
search: PA, Writing: PA, EK, Approval: EK.